Market Overview

UPDATE: Morgan Stanley Initiates Optimer Pharmaceuticals at Underweight on Risk/Reward

Related OPTR
HSR Waiting Period Expires for Cubist, Optimer Deal
Cubist Pharma Reports Pricing of $700M in Convertible Senior Notes, Expecting Proceeds of $679M

Morgan Stanley initiated coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with an Underweight rating and a $11 price target.

Morgan Stanley noted, "Optimer's growth driver is Dificid, approved for treatment of C. diff. Dificid is a best in disease therapy, but reimbursement hurdles, sluggish launch trends, and a lack of clear long-term growth drivers limit our sales expectations (2018 WW revenue ~$285mn). We see OPTR's risk reward as less attractive than others in our coverage universe."

Optimer Pharmaceuticals closed at $12.82 on Wednesday.

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (OPTR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters